BioSpace News Archive

Sensorion announces that the US Food and Drug Administration has granted Rare Pediatric Disease Designation to the Company’s lead therapy gene candidate, OTOF-GT, a gene therapy intended for the treatment of otoferlin gene mediated hearing loss.

Nykode Therapeutics ASA announced that its Chief Executive Officer, Michael Engsig, and Chief Business Officer & Co-founder, Agnete Fredriksen, will present and host 1x1 meetings at two upcoming investor conferences in November.

Photocure ASA., announces that The United States Centers for Medicare & Medicaid Services has released final payment rates in connection with the recently approved Medicare reimbursement changes for Blue Light Cystoscopy with Cysview® in the hospital outpatient and ambulatory surgical center sites of care.

Singleron Biotechnologies is happy to announce the opening of their brand-new laboratories in Cologne, Germany, dedicated to showcasing their vast single cell sequencing solutions, from instruments to novel kits tailored for many different research applications.

Calliditas Therapeutics AB announced that it will host a Key Opinion Leader Fireside Chat on the IgA Nephropathy treatment landscape in the US on Tuesday, November 8th, 2022 at 1:30pm Eastern Time.

Cerveau Technologies, Inc. announced a license agreement with LEXEO Therapeutics, Inc., which will enable LEXEO to use Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography scans to assess the status and progression of neurofibrillary tangles in the brain.

BrainStorm Cell Therapeutics Inc. announced the presentation of a poster with new analyses from NurOwn’s placebo-controlled Phase 3 amyotrophic lateral sclerosis trial that account for limitations in the Revised ALS Functional Rating Scale and provide evidence of a clinically meaningful treatment effect.

BioNTech SE reported financial results for the three and nine months ended September 30, 2022 and provided an update on its corporate progress.

NRx Pharmaceuticals, Inc., a clinical-stage CNS biopharmaceutical company, announced that it has obtained approximately $11 million in unsecured debt financing from Streeterville Capital, LLC, a Utah limited liability company.

Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Ypsomed AG, the manufacturer and supplier of the pen injector device to be used in connection with its biosimilar insulin glargine and biosimilar insulin aspart development programs.